GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current FDA-Approved Treatment for Sickle Cell Disease
- Data on lead drug candidate, rivipansel (GMI-1070), highlighted via
oral presentation and poster at 8th Annual
Rivipansel is in clinical trials as a potential therapy for the
treatment of vaso-occlusive crisis (VOC) in people with sickle cell
disease. It has previously received both Orphan Drug and Fast Track
status for the treatment of VOC from the
"As we look to see rivipansel enter Phase 3 studies later this year, we
are pleased with the opportunity to share data for the program at the
8th Annual
The oral presentation by
About Sickle Cell Disease
There are more than 90,000 people in the U.S. with sickle cell disease, and many of them have multiple, acute VOCs annually. These painful crises result in more than 73,000 hospitalizations per year in the U.S., with an average stay of approximately six days.
About Rivipansel
Rivipansel is being developed in partnership with Pfizer to treat
vaso-occlusive crisis of sickle cell disease (VOC). The compound is a
synthetic glycomimetic molecule, which was rationally designed to
inhibit all three selectin types (a pan-selectin inhibitor). Selectins
are glycoprotein cell adhesion molecules implicated in inflammatory
processes. To achieve adequate therapeutic activity in certain
inflammatory disorders, inhibition of all three selectin types
(E-selectin, L-selectin and P-selectin) may be required. We therefore
believe that rivipansel's ability to inhibit all selectins will provide
distinct advantages over other approaches that target only one selectin,
or which are so broadly active as to be non-specific.
About
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of GMI-1070 and other matters. Actual results may differ
materially from those in these forward-looking statements. For a further
description of the risks associated with these statements, as well as
other risks facing
Email: bhahn@glycomimetics.com
Source:
News Provided by Acquire Media